Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761215 | 0.79 | UGT2B17 (0.36) | HTR1DHTR1BUHRF1PARP10PARP11 | |
| SCHEMBL20939380 | 0.78 | NOTUM (0.42) | UHRF1PARP10PARP11PARP1NOTUM | |
| SCHEMBL24304266 | 0.78 | NOTUM (0.34) | PARP10PARP11PARP1NOTUMALDH1A1 | |
| SCHEMBL10118878 | 0.77 | ADRA2A (0.41) | HTR1DHTR1BUHRF1PARP10PARP11 | |
| SCHEMBL14234585 | 0.76 | DRD2 (0.37) | PARP10PARP11PARP1NOTUMALDH1A1 | |
| SCHEMBL23384792 | 0.76 | UHRF1 (0.34) | UHRF1PARP10PARP11PARP1NOTUM | |
| SCHEMBL31443670 | 0.76 | DRD2 (0.37) | PARP10PARP11PARP1NOTUMALDH1A1 | |
| SCHEMBL1613135 | 0.76 | HTR2A (0.39) | L3MBTL1 | |
| SCHEMBL21903872 | 0.73 | KDM1A (0.33) | UHRF1PARP10PARP11PARP1NOTUM | |
| SCHEMBL20425892 | 0.73 | PNMT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4526289-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119546574-A | Antiviral indolinyl compounds and uses thereof | 吉利德科学公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2023225162-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225162-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | MAVS, IRF3, EIF2AK2 | HTR1D 2627/4885HTR1B 2530/4885UHRF1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.